Following its Annual General Meeting, Curasight has announced changes to its Board of Directors. As Lars Trolle and Charlotte Vedel step down, the company welcomes Dr Marcel Reichen and Dr Colin Hayward as new board members. The additions aim to expand the board's international expertise within the radiopharmaceutical space as the company approaches key clinical milestones. BioStock contacted CEO Ulrich Krasilnikoff to learn more.
Read the full interview at biostock.se:
Curasight welcomes international radiopharma experts to the board
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/